Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.
Radar 87 (high attention) · dilution pressure high · listing risk high · governance risk elevated · runway 4.9 mo · strongest signal: MVLS deficiency (Aug 3, 2026)
What would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy.
What would prove it wrong: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 228 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 14, 2026 | ▼ Late filing (NT) | NT 10-Q filed 2026-08-14 filing | 47 |
| Aug 3, 2026 | ▼ MVLS deficiency | “mvls deficiency” language in 8-K (8-K) filed 2026-08-03 filing | 51 |
| Aug 3, 2026 | ▼ PIPE | “pipe” language in 8-K (EX-10.1) filed 2026-08-03 filing | 38 |
| Aug 3, 2026 | ▼ Unregistered sale | 8-K Item 3.02 filed 2026-08-03 (accepted 08:37 ET) filing | 32 |
| Aug 3, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (EX-10.1) filed 2026-08-03 filing | 32 |
| Jul 31, 2026 | ▼ Going-concern language | “going concern periodic” language in 10-Q (10-Q) filed 2026-07-31 filing | 25 |
| Jul 29, 2026 | ▼ Equity deficiency | “stockholders equity deficiency” language in 8-K (8-K) filed 2026-07-29 filing | 42 |
| Dec 31, 2025 | ▼ Share count +25% | Shares outstanding 1,616,081 (2026-06-04) -> 2,108,277 (2026-07-31), +30% filing | 34 |
| Dec 31, 2025 | ▼ Negative equity | Stockholders' equity $-8,812,688 as of 2026-03-31 filing | 31 |
| Dec 31, 2025 | ▼ Runway < 6 months | ~4.9 months runway: liquidity $3,086,770 as of 2025-12-31, burn $7,528,859/yr (latest fiscal-year operating cash flow (quarter too short to annualize) [companyfacts]) filing | 29 |
| Dec 31, 2025 | ▼ Cash < current liabilities | Liquidity $3,086,770 vs current liabilities $12,063,261 filing | 21 |
VIVS VivoSim Labs, INC. · DAIC CID Holdco, Inc. · NCRA NOCERA, INC. · GNPX Genprex, Inc. · FLD Fold Holdings, Inc. · HCWB HCW Biologics Inc. · screener →